⌘K
Loading industry…
Pharmaceutical Products is ranked #3 of 49 industries by 3-month relative strength, with +22.09% excess return vs the S&P 500 over the last 63 trading days. It sits inside the Health Care GICS sector and contains 587 stocks.
Climbing
Strength is spread across many constituents. Healthier rotation; setups likely available beyond the obvious names.
Insufficient bar history to compute breadth for this industry.
As of May 21, 2026, the pharmaceutical products industry is ranked #3 of 49by 3-month relative strength versus the S&P 500. It is currently outperforming the market, with an excess return of +22.09% over the past 63 trading days.
The 1-month rank is #1, the 6-month rank is #11, and the 1-year rank is #0. Compare these to spot a rotation: a falling 6M rank with a rising 1M rank tells you the industry is turning — money is starting to come back.
The 587 constituents are ranked by relative strength above. See the full constituents table for per-name RS.
How many stocks are in this industry?
587 core-list common stocks and ADRs. We include only names with enough trading history to compute relative strength.
What GICS sector is this in?
Health Care. FF49 and GICS are different taxonomies; the mapping is a rough one-to-many — see the siblings card for other FF49 industries in the same GICS sector.
How is the RS number computed?
We take the constituent log-returns over the lookback window, subtract SPY's log-return over the same window, and aggregate on a market-cap-weighted basis. The result is “excess return vs the market.”
Pharmaceutical Products is one of 49 industries in the Fama-French taxonomy. SIC code-based classification published monthly by Ken French at Dartmouth. The FF49 groupings are intentionally coarser than GICS or SIC alone — useful for market-rotation reads, less useful for fine-grained screening.
FF49 is intentionally coarse — useful for rotation reads, less useful for fine-grained screening. Read the methodology →